CANCER TYPE
AGE RANGE
CANCER RISK
RISK FOR GENERAL POPULATION
Pancreatic Neuroendocrine Tumors (PNET)
Lifetime risk
Up to 80%
<0.1%
Other MEN1-associated tumors and cancers
To age 80
Up to 100%
N/A
MEN1
Associated Syndrome
Multiple Endocrine Neoplasia Type 1 (MEN Type
Core Cancer Risk(s)
Endocrine Cancer (Most common is tumors of the parathyroid gland)
Inheritance
Autosomal Dominant
Prevalence
Unknown
CANCER TYPE
PROCEDURE
AGE TO BEGIN
FREQUENCY
Pancreatic Neuroendocrine Tumors (PNET)
Clinical screening for symptoms
10 years
Individualized
Biochemical screening
10 years
Annually
Consider abdominal/pelvic CT or MRI with contrast
10 years
Every 1 to 3 years
Consider serial endoscopic ultrasound
Individualized
Individualized
Other MEN1-associated tumors and cancers
Multiple screenings recommended, including clinical screening for symptoms, biochemical screening, and imaging with MRI, CT, ultrasound and other methods
Some screenings are recommended to begin as early as age 5
Variable by procedure